Imugene (IMU) investor relations material

Executive summary

• Focused on advancing azer-cel, an off-the-shelf allogeneic CAR T therapy for blood cancers, with three active clinical trial cohorts across the US and Australia.

• Discontinued non-core programs (CF33, onCARlytics, PD1-Vaxx) to prioritize azer-cel.

• Strengthened board with two new non-executive directors and transitioned CEO role.

Financial highlights

• Reported FY26 net loss of $105.3 million, up 123% year-over-year, mainly due to non-cash R&D impairments and milestone payments.

• Cash and cash equivalents at June 30, 2026: $2.6 million, with $11.1 million raised in July 2026.

• Reduced payments to suppliers and employees by 40%, headcount by 42%, and employee benefits costs by 45% compared to FY25.

• Completed three capital raisings totaling ~$52 million and received a $2.7 million R&D tax refund.

Outlook and guidance

• Ongoing Phase 1b trials for azer-cel in three cohorts, with further data and potential pivotal studies planned.

• No short- or medium-term product revenue expected; focus remains on clinical development and regulatory milestones.

• Additional capital raising anticipated to support operations.